Codelivery of GRP78 siRNA and docetaxel via RGD-PEG-DSPE/DOPA/CaP nanoparticles for the treatment of castration-resistant prostate cancer

Background: Castration-resistant prostate cancer (CRPC) accounts for the majority of prostate cancer deaths, and patients with CRPC are prone to developing drug resistance. Therefore, there is a need to develop effective therapeutics to treat CRPC, especially drug-resistant CRPC. Although various na...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xiangyu, He, Zelai, Xiang, Longquan, Li, Liang, Zhang, Haiyan, Lin, Fanzhong, Cao, Hongying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499149/
https://www.ncbi.nlm.nih.gov/pubmed/31118572
http://dx.doi.org/10.2147/DDDT.S198400

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6499149/
https://www.ncbi.nlm.nih.gov/pubmed/31118572
http://dx.doi.org/10.2147/DDDT.S198400

Ejemplares similares